Search SAMHSA Publications and Digital Products
Store Facets Summary
- Clear all filters
- Remove Prevention Professionals
- Remove Program Planners, Administrators, & Project Managers
- Remove Older Adults as Audience
- Remove People with Substance Use or Abuse Problems as Audience
- Remove Women as Audience
- Remove English
- Remove Alcohol
- Remove Over-the-Counter Drugs
- Remove Heroin
- Remove Awareness
- Remove Medication-Assisted Treatment
- Remove Naltrexone
- Remove Alternative Therapy
Main page content
Published: August 2021
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Published: July 2021
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
Published: January 2021
This Advisory, based on TIP 49, Incorporating Alcohol Pharmacotherapies Into Medical Practice, focuses on medication and related treatment decisions made after screening and assessment for AUD, and medically supervised withdrawal, if necessary. Alcohol consumption should not stop abruptly in those patients who have consumed alcohol regularly over a prolonged period of time. This Advisory is meant as an overview of AUD medications to facilitate abstinence.